A Transformational Gift Opens New Possibilities in Cancer and Microbiome Research
A $5 million gift from the Mario Lemieux Foundation will establish the Mario Lemieux Microbiome Innovation Center at UPMC Hillman Cancer Center, advancing research into one of the most promising frontiers in cancer care.
By Kaitlin Busch
A $5 million gift from the Mario Lemieux Foundation to the University of Pittsburgh will establish the Mario Lemieux Microbiome Innovation Center at UPMC Hillman Cancer Center. The center will bring researchers together to explore how the body’s microbiome shapes the way cancer develops, progresses, and responds to treatment. UPMC will further amplify the impact of this gift with a $1 million contribution.
The new center will unite experts in cancer biology, immunology, microbiome science, computational biology, and clinical research to examine how the microbiome may influence cancer prevention, diagnosis, treatment, and survivorship.
The microbiome — the community of bacteria, fungi, and other microbes living in and on our bodies — is emerging as an important frontier in cancer research. Scientists are learning that these microbes can affect inflammation, immune response, treatment resistance, side effects, and a patient’s response to therapies such as immunotherapy.
For people facing cancer, this growing field could lead to more personalized care by helping clinicians predict which treatments are most likely to work, address treatment resistance, improve responses to immunotherapy, and develop microbiome-based strategies for solid tumors and blood cancers.
“Every patient’s cancer journey is different. By bringing together information about each person’s unique biology and circumstances — including their health, treatment, lifestyle, diet, and outcomes — researchers can begin to understand why some treatments work well for one patient but not another,” said Lauren Lemieux Antoni, treasurer of the board of directors of the Mario Lemieux Foundation. “The goal is simple: to learn faster and bring new discoveries to patients sooner. This research will help our amazing doctors at UPMC Hillman choose better treatments and improve how patients respond to care.”
“UPMC Hillman investigators are already making internationally recognized discoveries in this area, with important implications for patients with both solid tumors and blood cancers. This center will build on that momentum by providing shared tools and resources that enable researchers to collaborate more effectively,” said John C. Byrd, MD, director, UPMC Hillman Cancer Center. “The goal is not discovery for discovery’s sake. The goal is to translate this work into pilot clinical trials, new interventions, and more personalized treatment strategies for patients.”
Designed as a hub for collaboration, the Mario Lemieux Microbiome Innovation Center will connect UPMC Hillman and University of Pittsburgh investigators who are already advancing microbiome science. Shared infrastructure, working groups, common goals, and milestone-driven projects will strengthen collaboration across laboratories, disease areas, and clinical programs.
A key priority will be integrating microbiome biology with clinical data, AI-enabled analytics, tumor and immune profiling, lifestyle and dietary information, and microbiome samples collected across the health system. Examining these factors together may reveal how microbes, tumors, treatments, and individual patient characteristics interact — and how those insights could guide future care.
Support from the Mario Lemieux Foundation will fuel pilot studies, advanced research infrastructure, sample collection, sophisticated data analytics, and the recruitment of leading scientific talent.
“That kind of support is essential because it gives scientists the freedom to pursue bold questions that may one day change the standard of care,” said Dr. Byrd.
The gift also carries forward the Mario Lemieux Foundation’s enduring commitment to patients and families affected by cancer.
“When the Foundation began, we could not have imagined all the ways it would grow or the innovative research it would one day help make possible. But this is exactly why the Foundation exists: to support hope, progress, and exceptional cancer care for patients and families,” said Tom Grealish, president of the board of directors of the Mario Lemieux Foundation.
The gift also supports Proving Possible, the University of Pittsburgh’s $3 billion comprehensive fundraising campaign to accelerate innovation and discovery for the benefit of Pittsburgh, the Commonwealth, and the wider world.
The center builds on a partnership grounded in gratitude, progress, and hope for patients and families.
“As we begin this exciting new chapter through the Mario Lemieux Microbiome Innovation Center, we do so with gratitude, optimism, and renewed purpose,” said Stanley M. Marks, MD, chairman, UPMC Hillman Cancer Center. “Together, we are advancing innovation, accelerating discovery, and moving toward a future with better outcomes and greater hope for people facing cancer and their families.”